Pharmaceutical companies are indispensable for the development of new cancer treatments, but they also introduce certain risks. One major concern is the influence they may have on prescribing practices. Financial incentives or marketing pressures can sometimes lead to the promotion of certain drugs over others, which may not always be in the best interest of the patient. Moreover, drug shortages or recalls can disrupt treatment plans, posing additional risks to patients.
